MDT-AP-1333
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 39
- os_event
- false
- age_years
- 0.5
- sex
- M
- new_clusters
- S3
- umap1_2d
- -3.068592873
- umap2_2d
- -7.536391354
- umap1_3d
- -2.698198609
- umap2_3d
- -3.392707334
- umap3_3d
- 7.812666789
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.530
- CHOLESTEROL_HOMEOSTASIS+0.320
- COMPLEMENT+0.280
- FATTY_ACID_METABOLISM+0.280
- ALLOGRAFT_REJECTION+0.270
- MYOGENESIS+0.260
- INTERFERON_ALPHA_RESPONSE+0.250
- ADIPOGENESIS+0.220
- INTERFERON_GAMMA_RESPONSE+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.190
Top 10 suppressed
- G2M_CHECKPOINT-0.550
- E2F_TARGETS-0.510
- MITOTIC_SPINDLE-0.460
- WNT_BETA_CATENIN_SIGNALING-0.430
- MYC_TARGETS_V2-0.320
- TGF_BETA_SIGNALING-0.290
- DNA_REPAIR-0.140
- HEDGEHOG_SIGNALING-0.120
- UNFOLDED_PROTEIN_RESPONSE-0.120
- TNFA_SIGNALING_VIA_NFKB-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0709 | Med | Medulloblastoma | 0.879 |
| 2 | b734ed82-e267-4070-9a8f-190cbbd78766 | — | — | 0.838 |
| 3 | TCGA-49-4501-01A-01R-1206-07 | — | cohortA1 | 0.833 |
| 4 | ERR2598280 | fetal | fetal | 0.822 |
| 5 | TCGA-97-8177-01A-11R-2287-07 | — | cohortA1 | 0.815 |
| 6 | TCGA-OR-A5LA-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.814 |
| 7 | TCGA-67-3772-01A-01R-0946-07 | — | cohortA1 | 0.810 |
| 8 | SRR8518286 | — | F | 0.807 |
| 9 | ERR2598281 | fetal | fetal | 0.806 |
| 10 | MDT-AP-2183 | Med | Medulloblastoma | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.530 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |